Usefulness of Serum Leucine-rich Alpha 2 Glycoprotein in Crohn's Disease: Is There Any Difference between Small Intestine and Colonic Lesions?

被引:0
|
作者
Matsumoto, Satohiro [1 ]
Mashima, Hirosato [1 ]
机构
[1] Jichi Med Univ, Dept Gastroenterol, Saitama Med Ctr, 1-847 Amanuma, Saitama, Saitama 3308503, Japan
关键词
leucine-rich alpha-2 glycoprotein; cutoff value; delta value; mucosal healing; small intestine; Crohn's disease; INFLAMMATORY BOWEL DISEASES; FECAL CALPROTECTIN; ENDOSCOPIC ACTIVITY; MAGNETIC-RESONANCE; BIOMARKER; LACTOFERRIN; MARKER; SCORE; CRP;
D O I
10.1093/crocol/otad028
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Lay Summary The superiority of leucine-rich alpha 2 glycoprotein (LRG) to C-reactive protein (CRP) differs between small intestinal and colonic lesions. For Crohn's disease patients with ileum-dominant activity, monitoring of both LRG and CRP is necessary, instead of monitoring CRP alone. Background The usefulness of leucine-rich alpha 2 glycoprotein (LRG) to evaluate Crohn's disease (CD) activity differs among various intestinal lesions. We aimed to evaluate the association between endoscopic disease activity based on the Simple Endoscopic Score for Crohn's disease (SES-CD) and LRG level separately for small intestinal and colonic lesions. Methods We examined the correlation between LRG level and SES-CD and performed receiver operating characteristic (ROC) analysis to determine the LRG cutoff value in 141 patients who underwent endoscopy (total 235 measurements). Furthermore, the LRG cutoff value was analyzed by comparing small intestinal and colonic lesions. Results LRG levels were significantly higher in patients without mucosal healing than in those with mucosal healing (15.9 mu g/mL vs 10.5 mu g/mL, P < .0001). The LRG cutoff value for mucosal healing was 14.3 mu g/mL (area under the ROC curve [AUC]: 0.80; sensitivity: 0.89; specificity: 0.63). The LRG cutoff value for patients with type L1 was 14.3 mu g/mL (sensitivity: 0.91; specificity: 0.53), and that for patients with type L2 was 14.0 mu g/mL (sensitivity: 0.95; specificity: 0.73). The diagnostic performance (AUC) of LRG and C-reactive protein (CRP) for mucosal healing was, respectively, 0.75 and 0.60 (P = 0.01) in patients with type L1 and 0.80 and 0.85 (P = 0.90) in patients with type L2. Conclusions The optimal LRG cutoff value for evaluating mucosal healing in CD is 14.3 mu g/mL. LRG is more useful than CRP for predicting mucosal healing in patients with type L1. The superiority of LRG to CRP differs between small intestinal and colonic lesions.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Serum leucine-rich alpha-2 glycoprotein as a predictive factor of endoscopic remission in Crohn's disease
    Abe, Izuru
    Shiga, Hisashi
    Chiba, Hirofumi
    Miyazawa, Teruko
    Oomori, Shinya
    Shimoyama, Yusuke
    Moroi, Rintaro
    Kuroha, Masatake
    Kakuta, Yoichi
    Kinouchi, Yoshitaka
    Masamune, Atsushi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (09) : 1741 - 1748
  • [2] Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn's Disease
    Kawamura, Tatsuya
    Yamamura, Takeshi
    Nakamura, Masanao
    Maeda, Keiko
    Sawada, Tsunaki
    Ishikawa, Eri
    Iida, Tadashi
    Mizutani, Yasuyuki
    Ishikawa, Takuya
    Kakushima, Naomi
    Furukawa, Kazuhiro
    Ohno, Eizaburo
    Honda, Takashi
    Kawashima, Hiroki
    Ishigami, Masatoshi
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (02) : 245 - 253
  • [3] Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker For Small Bowel Mucosal Activity in Crohn's Disease
    Kawamoto, Ami
    Takenaka, Kento
    Hibiya, Shuji
    Ohtsuka, Kazuo
    Okamoto, Ryuichi
    Watanabe, Mamoru
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (05) : E1196 - E1200
  • [4] Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker for Transmural Inflammation in Crohn's Disease
    Takenaka, Kento
    Kitazume, Yoshio
    Kawamoto, Ami
    Fujii, Toshimitsu
    Udagawa, Yumi
    Wanatabe, Ryosuke
    Shimizu, Hiromichi
    Hibiya, Shuji
    Nagahori, Masakazu
    Ohtsuka, Kazuo
    Sato, Hiroyuki
    Hirakawa, Akihiro
    Watanabe, Mamoru
    Okamoto, Ryuichi
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (06): : 1028 - 1035
  • [5] Efficacy of serum leucine-rich alpha-2 glycoprotein in predicting findings of Crohn's disease small bowel lesion in capsule endoscopy
    Omori, Teppei
    Koroku, Miki
    Murasugi, Shun
    Ito, Ayumi
    Yonezawa, Maria
    Nakamura, Shinichi
    Tokushige, Katsutoshi
    INTESTINAL RESEARCH, 2024,
  • [6] Effectiveness of Leucine-Rich Alpha-2 Glycoprotein for a Pediatric Patient with Crohn Disease
    Kakiuchi, Toshihiko
    Yoshiura, Masato
    INDIAN JOURNAL OF PEDIATRICS, 2023, 90 (03): : 307 - 307
  • [7] Usefulness of Serum Leucine-Rich Alpha-2 Glycoprotein as a Disease Activity Biomarker in Patients with Rheumatoid Arthritis
    Ha, You Jung
    Kang, Eun-Jin
    Lee, Sang-Won
    Lee, Soo-Kon
    Park, Yong-Beom
    Song, Jung-Soo
    Choi, Sang Tae
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2014, 29 (09) : 1199 - 1204
  • [8] Effectiveness of Leucine-Rich Alpha-2 Glycoprotein for a Pediatric Patient with Crohn Disease
    Toshihiko Kakiuchi
    Masato Yoshiura
    Indian Journal of Pediatrics, 2023, 90 : 307 - 307
  • [9] SERUM LEUCINE-RICH ALPHA-2 GLYCOPROTEIN LEVELS FOR PREDICTING ACTIVE ULTRASONOGRAPHIC FINDINGS IN INTESTINAL LESIONS OF PATIENTS WITH CROHN'S DISEASE IN CLINICAL REMISSION
    Nasuno, Masanao
    Shimazaki, Hiroshi
    Nojima, Masanori
    Hamada, Takahito
    Sugiyama, Kohei
    Miyakawa, Maki
    Tanaka, Hiroki
    GASTROENTEROLOGY, 2023, 164 (06) : S1220 - S1220
  • [10] Serum leucine-rich alpha-2 glycoprotein levels for predicting active ultrasonographic findings in intestinal lesions of patients with Crohn's disease in clinical remission
    Nasuno, Masanao
    Shimazaki, Hiroshi
    Nojima, Masanori
    Hamada, Takahito
    Sugiyama, Kohei
    Miyakawa, Maki
    Tanaka, Hiroki
    MEDICINE, 2023, 102 (32) : E34628